Shanghai Heartcare IPO: Thoughts on First Day Trading
351 Views19 Aug 2021 19:29
We expect Heartcare’s IPO to remain under pressure at its open due to uncertainty regarding the lawsuit with Medtronics despite being priced at a significant discount to Zylox-Tonbridge’s multiples.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
- Beijing 4Paradigm IPO: Strong Business Model and Impressive Growth Profile19 Oct 2021
- MicroTech Medical IPO: Thoughts on First Day Trading18 Oct 2021
- MicroTech Medical IPO: Forecasts and Valuation07 Oct 2021
- Shanghai Heartcare IPO: Thoughts on First Day Trading19 Aug 2021
- Shanghai Heartcare IPO: DCF Offers Decent Upside but Mind the Ongoing Lawsuit with Medtronic12 Aug 2021
- Medlive IPO: Thoughts on First Day Trading15 Jul 2021
- Zylox-Tonbridge IPO: DCF Valuation Offers Decent Upside to the Upper End24 Jun 2021
x